ZA200603719B - Methods of using and compositions comprising a JNK inhibitor for the treatment and management of asbestos-related diseases and disorders - Google Patents

Methods of using and compositions comprising a JNK inhibitor for the treatment and management of asbestos-related diseases and disorders Download PDF

Info

Publication number
ZA200603719B
ZA200603719B ZA200603719A ZA200603719A ZA200603719B ZA 200603719 B ZA200603719 B ZA 200603719B ZA 200603719 A ZA200603719 A ZA 200603719A ZA 200603719 A ZA200603719 A ZA 200603719A ZA 200603719 B ZA200603719 B ZA 200603719B
Authority
ZA
South Africa
Prior art keywords
heterocycle
aryl
alkyl
occurrence
arylalkyl
Prior art date
Application number
ZA200603719A
Other languages
English (en)
Inventor
Jerome B Zeldis
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of ZA200603719B publication Critical patent/ZA200603719B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200603719A 2003-11-06 2004-11-04 Methods of using and compositions comprising a JNK inhibitor for the treatment and management of asbestos-related diseases and disorders ZA200603719B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51860103P 2003-11-06 2003-11-06

Publications (1)

Publication Number Publication Date
ZA200603719B true ZA200603719B (en) 2007-09-26

Family

ID=34590281

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200603719A ZA200603719B (en) 2003-11-06 2004-11-04 Methods of using and compositions comprising a JNK inhibitor for the treatment and management of asbestos-related diseases and disorders

Country Status (11)

Country Link
US (1) US20070270448A1 (enExample)
EP (1) EP1684690A4 (enExample)
JP (1) JP2007510671A (enExample)
KR (1) KR20060124610A (enExample)
CN (1) CN1901903A (enExample)
AU (1) AU2004288715A1 (enExample)
BR (1) BRPI0416266A (enExample)
CA (1) CA2544591A1 (enExample)
IL (1) IL175428A0 (enExample)
WO (1) WO2005046594A2 (enExample)
ZA (1) ZA200603719B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ590320A (en) 2008-07-14 2012-12-21 Gilead Sciences Inc Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
NZ590283A (en) 2008-07-14 2012-11-30 Gilead Sciences Inc Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
US20100183633A1 (en) * 2008-12-04 2010-07-22 University Of Massachusetts Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
US8283357B2 (en) 2009-06-08 2012-10-09 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
KR20120031170A (ko) 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
AU2017313847A1 (en) * 2016-08-19 2019-02-28 Memorial Sloan-Kettering Cancer Center Methods of differentiating stem cells into endoderm
CN113698408B (zh) * 2020-05-22 2025-07-25 武汉朗来科技发展有限公司 Jnk抑制剂、其药物组合物和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095415A (en) * 1958-05-30 1963-06-25 Ciba Ltd Anthraquinone dyestuffs containing a 2-chloro, 4-hydroxy (lower) alkylamino, triazinylamino group
CH428043A (fr) * 1965-08-16 1967-01-15 Sandoz Ag Procédé de fabrication de colorants de dispersion isothiazolantroniques
US3541110A (en) * 1967-01-20 1970-11-17 American Home Prod Indazole-5-sulfonamides
JPS63184364A (ja) * 1987-01-27 1988-07-29 Toshiba Corp 半導体装置の製造方法
PT851753E (pt) * 1995-09-19 2004-04-30 Fujisawa Pharmaceutical Co Composicoes em aerossol
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
EP0973767A1 (en) * 1997-03-31 2000-01-26 Dupont Pharmaceuticals Company Indazoles of cyclic ureas useful as hiv protease inhibitors
WO1999017798A1 (en) * 1997-10-02 1999-04-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
AU780306B2 (en) * 1999-08-19 2005-03-17 Signal Pharmaceuticals, Inc. Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions
US20040072888A1 (en) * 1999-08-19 2004-04-15 Bennett Brydon L. Methods for treating inflammatory conditions or inhibiting JNK
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
ATE430742T1 (de) * 2000-12-21 2009-05-15 Smithkline Beecham Corp Pyrimidinamine als angiogenesemodulatoren
US6987184B2 (en) * 2001-02-15 2006-01-17 Signal Pharmaceuticals, Llc Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related
WO2003075917A1 (en) * 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
CA2546493A1 (en) * 2003-11-19 2005-06-09 Signal Pharmaceuticals, Llc Indazole compounds and methods of use thereof as protein kinase inhibitors

Also Published As

Publication number Publication date
CA2544591A1 (en) 2005-05-26
WO2005046594A3 (en) 2005-09-22
JP2007510671A (ja) 2007-04-26
US20070270448A1 (en) 2007-11-22
EP1684690A4 (en) 2008-10-15
KR20060124610A (ko) 2006-12-05
AU2004288715A1 (en) 2005-05-26
CN1901903A (zh) 2007-01-24
WO2005046594A2 (en) 2005-05-26
EP1684690A2 (en) 2006-08-02
BRPI0416266A (pt) 2007-01-09
IL175428A0 (en) 2008-04-13

Similar Documents

Publication Publication Date Title
US7351729B2 (en) JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
ZA200603719B (en) Methods of using and compositions comprising a JNK inhibitor for the treatment and management of asbestos-related diseases and disorders
ES2437132T3 (es) Tratamiento combinado con inhibidores de PARP
ZA200507321B (en) Diphenylethylene compounds and uses thereof
US20050266391A1 (en) Methods for preserving tissue
JP2007534632A (ja) アスベスト関連疾患および障害の治療および管理のための免疫調節化合物の使用方法およびそれを含む組成物
JP2006512143A (ja) 薬剤被覆ステントおよびその使用方法
KR20050057673A (ko) Ｊｎｋ 억제제를 이용한 통증의 치료
JP2007500201A (ja) エクチナサイジン−７４３と白金抗腫瘍化合物との併用
NZ540187A (en) Methods for the treatment, prevention and management of macular degeneration
Buzdar New generation aromatase inhibitors–from the advanced to the adjuvant setting
JP2003512301A (ja) アロマターゼ阻害剤と更なる生理活性化合物とを含む併用治療法
US20220071967A1 (en) Method of treatment of shwachman-diamond syndrome
US7659310B2 (en) Methods of enhancing solubility of agents
JP2005029573A (ja) 腫瘍転移抑制剤
ZA200503469B (en) Methods for the treatment, prevention and management of macular degeneration
ZA200410101B (en) Compounds usefel for the treatment of cancer, compositions thereof and methods therewith
ES2263835T3 (es) Terapia combinada contra tumores que comprende derivados de distamicina acriloil sustituidos e inhibidores proteina quinasa (serina/treonina quinasa).
ZA200503242B (en) Treatment of pain with JNK inhibitors
CN101669958A (zh) 二膦酸类化合物的药物应用
Ackland Drug treatment of breast cancer
JP2005527552A (ja) 置換アクリロイルジスタマイシン誘導体および放射線療法を含む腫瘍に対する組合せ治療
RU2025113761A (ru) Производные антрациклина pnu и способы их применения
WO2022025150A1 (ja) 乳がん治療剤
KR20050016439A (ko) 질환-관련 쇠약증을 치료 또는 예방하기 위한 ｊｎｋ억제제를 사용하는 방법